Related Experiment Video

Updated: Aug 16, 2026

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline
08:40

Spatial and Temporal Analysis of Active ERK in the C. elegans Germline

Published on: November 29, 2016

Spatially separate docking sites on ERK2 regulate distinct signaling events in vivo

Christopher A Dimitri1, William Dowdle, Jeffrey P MacKeigan

  • 1Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA.

Current Biology : CB
|July 30, 2005
PubMed

Insights

Targeting the Ras-MAPK pathway for cancer therapy is challenging. Disrupting specific ERK2 docking interactions selectively inhibits downstream signaling, offering a novel therapeutic strategy without blocking essential cellular functions.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Oncology

Background:

  • The Ras-MAPK pathway is crucial in cell growth and proliferation, making it a key target for cancer therapeutics.
  • Inhibiting this pathway is complex due to MAPK's essential role in normal cellular functions.
  • MAPK substrate phosphorylation is regulated by protein-protein interactions involving docking sites.

Purpose of the Study:

  • To investigate the in vivo activity of ERK2 mutants with impaired docking site interactions.
  • To determine if selective inhibition of specific ERK2 signaling branches is possible.
  • To explore novel therapeutic strategies by targeting ERK-DEF domain interactions.

Main Methods:

  • Generated and analyzed ERK2 mutants with defects in DEF-domain or D-domain binding.
  • Assessed the activation of downstream effectors like RSK and Elk-1/TCF.
  • Evaluated nuclear translocation and target gene induction in response to mutations.

Main Results:

  • Mutations in the DEF-domain binding pocket selectively inhibited DEF-domain effectors but not D-domain containing RSK.
  • Mutations in the ERK2 CD domain selectively inhibited RSK but not DEF-domain signaling.
  • ERK2 phosphotransferase activity was unaffected by uncoupling docking interactions; DEF mutants were defective in Elk-1/TCF transactivation.

Conclusions:

  • Selective inhibition of specific ERK2 downstream signaling branches can be achieved by disrupting docking interactions.
  • Targeting ERK-DEF domain interactions presents a potential alternative therapeutic strategy for oncogenic Ras-MAPK signaling.
  • This approach could bypass the challenges associated with inhibiting the entire Ras-MAPK pathway.

More Related Videos

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development09:32

Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development

Published on: June 15, 2017

Related Concept Videos

Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Tail-anchoring of Proteins in the ER Membrane01:45

Tail-anchoring of Proteins in the ER Membrane

Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...